Inhibition of autoimmune diabetes in NOD mice by miRNA therapy

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Wang, Duncheng ^a,b,c   Shanina, Iryna ^b   Toyofuku, Wendy M ^a,b   Horwitz, Marc S ^b   Scott, Mark D ^a,b  

^a CANADIAN BLOOD SERVICES   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; ETANERCEPT; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; LYMPHOTOXIN; MICRORNA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BIOREACTOR; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE DIFFERENTIATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; UPREGULATION; ANIMAL; DIABETES MELLITUS, TYPE 1; IMMUNOLOGY; RNAI THERAPEUTICS;

ANIMALS; DIABETES MELLITUS, TYPE 1; MICE; MICE, INBRED NOD; RNAI THERAPEUTICS; T-LYMPHOCYTES, REGULATORY;

EID: 84956631058     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145179     Document Type: Article

References (53)

1. Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia. 2003; 46: 305-321. PMID: 12687328
2. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol. 2005; 23: 447-485. PMID: 15771578
3. Richer MJ, Lavallee DJ, Shanina I, Horwitz MS. Immunomodulation of antigen presenting cells promotes natural regulatory T cells that prevent autoimmune diabetes in NOD mice. PLoS One. 2012; 7: e31153. doi: 10.1371/journal.pone.0031153 PMID: 22355341
4. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000; 12: 431-440. PMID: 10795741
5. Gregori S, Giarratana N, Smiroldo S, Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol. 2003; 171: 4040-4047. PMID: 14530324
6. You S, Belghith M, Cobbold S, Alyanakian MA, Gouarin C, Barriot S, et al. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes. 2005; 54: 1415-1422. PMID: 15855328
7. Tritt M, Sgouroudis E, d'Hennezel E, Albanese A, Piccirillo CA. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes. 2008; 57: 113-123. PMID: 17928397
8. Richer MJ, Straka N, Fang D, Shanina I, Horwitz MS. Regulatory T-cells protect from type 1 diabetes after induction by coxsackievirus infection in the context of transforming growth factor-beta. Diabetes. 2008; 57: 1302-1311. doi: 10.2337/db07-1460 PMID: 18268045
9. D'Alise AM, Auyeung V, Feuerer M, Nishio J, Fontenot J, Benoist C, et al. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci U S A. 2008; 105: 19857-19862. doi: 10.1073/pnas.0810713105 PMID: 19073938
10. Feuerer M, Shen Y, Littman DR, Benoist C, Mathis D. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity. 2009; 31: 654-664. doi: 10. 1016/j.immuni.2009.08.023 PMID: 19818653
11. Nishio J, Feuerer M, Wong J, Mathis D, Benoist C. Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. J Exp Med. 2010; 207: 1879-1889. doi: 10.1084/jem.20100205 PMID: 20679403
12. Thayer TC, Wilson SB, Mathews CE. Use of nonobese diabetic mice to understand human type 1 diabetes. Endocrinol Metab Clin North Am. 2010; 39: 541-561. doi: 10.1016/j.ecl.2010.05.001 PMID: 20723819
13. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4 (+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes. 2005; 54: 92-99. PMID: 15616015
14. Noorchashm H, Kwok W, Rabinovitch A, Harrison LC. Immunology of IDDM. Diabetologia. 1997; 40 Suppl 3: B50-57. PMID: 9345646
15. Ryan EA, Lakey JR, Rajotte RV, Korbutt GS, Kin T, Imes S, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes. 2001; 50: 710-719. PMID: 11289033
16. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000; 343: 230-238. PMID: 10911004
17. Thomas D, Zaccone P, Cooke A. The role of regulatory T cell defects in type I diabetes and the potential of these cells for therapy. Rev Diabet Stud. 2005; 2: 9-18. PMID: 17491654
18. Luo X, Herold KC, Miller SD. Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity. 2010; 32: 488-499. doi: 10.1016/j.immuni.2010.04.002 PMID: 20412759
19. Lin MS, Tse HM, Delmastro MM, Bertera S, Wong CT, Lakomy R, et al. A multivalent vaccine for type 1 diabetes skews T cell subsets to Th2 phenotype in NOD mice. Immunol Res. 2011; 50: 213-220. doi: 10.1007/s12026-011-8215-0 PMID: 21717080
20. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120: 15-20. PMID: 15652477
21. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 2007; 8: 93-103. PMID: 17230196
22. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of micro- RNAs. Genome Res. 2009; 19: 92-105. doi: 10.1101/gr.082701.108 PMID: 18955434
23. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215-233. doi: 10. 1016/j.cell.2009.01.002 PMID: 19167326
24. Wei B, Pei G. microRNAs: critical regulators in Th17 cells and players in diseases. Cell Mol Immunol. 2010; 7: 175-181. doi: 10.1038/cmi.2010.19 PMID: 20364159
25. Guay C, Roggli E, Nesca V, Jacovetti C, Regazzi R. Diabetes mellitus, a microRNA-related disease? Transl Res. 2011; 157: 253-264. doi: 10.1016/j.trsl.2011.01.009 PMID: 21420036
26. Nielsen LB, Wang C, Sorensen K, Bang-Berthelsen CH, Hansen L, Andersen ML, et al. Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res. 2012; 2012: 896362. doi: 10.1155/2012/896362 PMID: 22829805
27. Bhardwaj A, Singh S, Singh AP. MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs. Mol Cell Pharmacol. 2010; 2: 213-219. PMID: 21289871
28. Braicu C, Calin GA, Berindan-Neagoe I. MicroRNAs and Cancer Therapy-from Bystanders to Major Players. Curr Med Chem. 2013
29. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005; 309: 1577-1581. PMID: 16141076
30. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17: 211-215. doi: 10. 1038/nm.2284 PMID: 21240262
31. Murad KL, Gosselin EJ, Eaton JW, Scott MD. Stealth cells: prevention of major histocompatibility complex class II-mediated T-cell activation by cell surface modification. Blood. 1999; 94: 2135-2141. PMID: 10477744
32. Chen AM, Scott MD. Current and future applications of immunological attenuation via pegylation of cells and tissue. BioDrugs. 2001; 15: 833-847. PMID: 11784214
33. Chen AM, Scott MD. Immunocamouflage: prevention of transfusion-induced graft-versus-host disease via polymer grafting of donor cells. J Biomed Mater Res A. 2003; 67: 626-636. PMID: 14566806
34. Chen AM, Scott MD. Comparative analysis of polymer and linker chemistries on the efficacy of immunocamouflage of murine leukocytes. Artif Cells Blood Substit Immobil Biotechnol. 2006; 34: 305-322. PMID: 16809132
35. Le Y, Scott MD. Immunocamouflage: the biophysical basis of immunoprotection by grafted methoxypoly( ethylene glycol) [mpeg]. Acta Biomater. 2010; 6: 2631-2641. doi: 10.1016/j.actbio.2010.01.031 PMID: 20109585
36. Wang D, Toyofuku WM, Chen AM, Scott MD. Induction of immunotolerance via mPEG grafting to allogeneic leukocytes. Biomaterials. 2011; 32: 9494-9503. doi: 10.1016/j.biomaterials.2011.08.061 PMID: 21885118
37. Wang D, Toyofuku WM, Scott MD. The potential utility of methoxypoly(ethylene Glycol)-mediated prevention of rhesus blood group antigen RhD recognition in transfusion medicine. Biomaterials. 2012; 33: 3002-3012. doi: 10.1016/j.biomaterials.2011.12.041 PMID: 22264524
38. Kyluik-Price DL, Li L, Scott MD. Comparative efficacy of blood cell immunocamouflage by membrane grafting of methoxypoly(ethylene glycol) and polyethyloxazoline. Biomaterials. 2014; 35: 412-422. doi: 10.1016/j.biomaterials.2013.09.016 PMID: 24074839
39. Montana E, Bonner-Weir S, Weir GC. Beta cell mass and growth after syngeneic islet cell transplantation in normal and streptozocin diabetic C57BL/6 mice. J Clin Invest. 1993; 91: 780-787. PMID: 8450059
40. Cortes JR, Sanchez-Diaz R, Bovolenta ER, Barreiro O, Lasarte S, Matesanz-Marin A, et al. Maintenance of immune tolerance by Foxp3+ regulatory T cells requires CD69 expression. J Autoimmun. 2014; 55: 51-62. doi: 10.1016/j.jaut.2014.05.007 PMID: 24934597
41. Shen E, Zhao K, Wu C, Yang B. The suppressive effect of CD25+Treg cells on Th1 differentiation requires cell-cell contact partially via TGF-beta production. Cell Biol Int. 2011; 35: 705-712. doi: 10. 1042/CBI20100528 PMID: 21314640
42. Balasa B, Krahl T, Patstone G, Lee J, Tisch R, McDevitt HO, et al. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol. 1997; 159: 4620-4627. PMID: 9379064
43. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998; 16: 111-135. PMID: 9597126
44. Creusot RJ, Chang P, Healey DG, Tcherepanova IY, Nicolette CA, Fathman CG. A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice. Mol Ther. 2010; 18: 2112-2120. doi: 10.1038/mt.2010.146 PMID: 20628358
45. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med. 1999; 5: 601-604. PMID: 10371488
46. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature. 2008; 453: 1051-1057. doi: 10.1038/nature07036 PMID: 18563156
47. Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol. 2007; 19: 362-371. PMID: 18035554
48. Korn T, Mitsdoerffer M, Croxford AL, Awasthi A, Dardalhon VA, Galileos G, et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A. 2008; 105: 18460-18465. doi: 10.1073/pnas.0809850105 PMID: 19015529
49. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009; 27: 485-517. doi: 10.1146/annurev.immunol.021908.132710 PMID: 19132915
50. Gaudreau S, Guindi C, Menard M, Besin G, Dupuis G, Amrani A. Granulocyte-macrophage colonystimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4+CD25+ regulatory T cells. J Immunol. 2007; 179: 3638-3647. PMID: 17785799
51. Kriegel MA, Rathinam C, Flavell RA. Pancreatic islet expression of chemokine CCL2 suppresses autoimmune diabetes via tolerogenic CD11c+ CD11b+ dendritic cells. Proc Natl Acad Sci U S A. 2012; 109: 3457-3462. doi: 10.1073/pnas.1115308109 PMID: 22328150
52. Yang H, Cheng EY, Sharma VK, Lagman M, Chang C, Song P, et al. Dendritic cells with TGF-beta1 and IL-2 differentiate naive CD4+ T cells into alloantigen-specific and allograft protective Foxp3+ regulatory T cells. Transplantation. 2012; 93: 580-588. doi: 10.1097/TP.0b013e318244dd67 PMID: 22270834
53. Tang X, Tian X, Zhang Y, Wu W, Tian J, Rui K, et al. Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis. Clin Dev Immunol. 2013; 2013: 345347. doi: 10.1155/2013/345347 PMID: 24288551